IBDEI1R4 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,29323,0)
 ;;=L03.022^^135^1361^18
 ;;^UTILITY(U,$J,358.3,29323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29323,1,3,0)
 ;;=3^Acute Lymphangitis of Left Finger
 ;;^UTILITY(U,$J,358.3,29323,1,4,0)
 ;;=4^L03.022
 ;;^UTILITY(U,$J,358.3,29323,2)
 ;;=^5009023
 ;;^UTILITY(U,$J,358.3,29324,0)
 ;;=L03.031^^135^1361^111
 ;;^UTILITY(U,$J,358.3,29324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29324,1,3,0)
 ;;=3^Cellulitis of Right Toe
 ;;^UTILITY(U,$J,358.3,29324,1,4,0)
 ;;=4^L03.031
 ;;^UTILITY(U,$J,358.3,29324,2)
 ;;=^5009025
 ;;^UTILITY(U,$J,358.3,29325,0)
 ;;=L03.032^^135^1361^104
 ;;^UTILITY(U,$J,358.3,29325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29325,1,3,0)
 ;;=3^Cellulitis of Left Toe
 ;;^UTILITY(U,$J,358.3,29325,1,4,0)
 ;;=4^L03.032
 ;;^UTILITY(U,$J,358.3,29325,2)
 ;;=^5009026
 ;;^UTILITY(U,$J,358.3,29326,0)
 ;;=L03.041^^135^1361^26
 ;;^UTILITY(U,$J,358.3,29326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29326,1,3,0)
 ;;=3^Acute Lymphangitis of Right Toe
 ;;^UTILITY(U,$J,358.3,29326,1,4,0)
 ;;=4^L03.041
 ;;^UTILITY(U,$J,358.3,29326,2)
 ;;=^5009028
 ;;^UTILITY(U,$J,358.3,29327,0)
 ;;=L03.042^^135^1361^20
 ;;^UTILITY(U,$J,358.3,29327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29327,1,3,0)
 ;;=3^Acute Lymphangitis of Left Toe
 ;;^UTILITY(U,$J,358.3,29327,1,4,0)
 ;;=4^L03.042
 ;;^UTILITY(U,$J,358.3,29327,2)
 ;;=^5009029
 ;;^UTILITY(U,$J,358.3,29328,0)
 ;;=M34.0^^135^1361^249
 ;;^UTILITY(U,$J,358.3,29328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29328,1,3,0)
 ;;=3^Progressive Systemic Sclerosis
 ;;^UTILITY(U,$J,358.3,29328,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,29328,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,29329,0)
 ;;=M34.1^^135^1361^91
 ;;^UTILITY(U,$J,358.3,29329,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29329,1,3,0)
 ;;=3^CR(E)ST Syndrome
 ;;^UTILITY(U,$J,358.3,29329,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,29329,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,29330,0)
 ;;=M34.2^^135^1361^273
 ;;^UTILITY(U,$J,358.3,29330,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29330,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,29330,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,29330,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,29331,0)
 ;;=M34.81^^135^1361^275
 ;;^UTILITY(U,$J,358.3,29331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29331,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,29331,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,29331,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,29332,0)
 ;;=M34.82^^135^1361^276
 ;;^UTILITY(U,$J,358.3,29332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29332,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
 ;;^UTILITY(U,$J,358.3,29332,1,4,0)
 ;;=4^M34.82
 ;;^UTILITY(U,$J,358.3,29332,2)
 ;;=^5011782
 ;;^UTILITY(U,$J,358.3,29333,0)
 ;;=M34.83^^135^1361^277
 ;;^UTILITY(U,$J,358.3,29333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29333,1,3,0)
 ;;=3^Systemic Sclerosis w/ Polyneuropathy
 ;;^UTILITY(U,$J,358.3,29333,1,4,0)
 ;;=4^M34.83
 ;;^UTILITY(U,$J,358.3,29333,2)
 ;;=^5011783
 ;;^UTILITY(U,$J,358.3,29334,0)
 ;;=M34.89^^135^1361^274
 ;;^UTILITY(U,$J,358.3,29334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29334,1,3,0)
 ;;=3^Systemic Sclerosis NEC
 ;;^UTILITY(U,$J,358.3,29334,1,4,0)
 ;;=4^M34.89
 ;;^UTILITY(U,$J,358.3,29334,2)
 ;;=^5011784
 ;;^UTILITY(U,$J,358.3,29335,0)
 ;;=M34.9^^135^1361^278
 ;;^UTILITY(U,$J,358.3,29335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29335,1,3,0)
 ;;=3^Systemic Sclerosis,Unspec
 ;;^UTILITY(U,$J,358.3,29335,1,4,0)
 ;;=4^M34.9
 ;;^UTILITY(U,$J,358.3,29335,2)
 ;;=^5011785
